XENE - Xenon Pharmaceuticals Inc.

QQQ $ 431.01 $ 6.55 (1.54 %)

DIA $ 382.27 $ 1.39 (0.36 %)

SPY $ 508.26 $ 4.77 (0.95 %)

TLT $ 88.26 $ 0.46 (0.52 %)

GLD $ 216.60 $ 0.70 (0.32 %)

Previous Close

$ 40.5

Open

$ 40.43

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 40.20 - $ 40.74

52 Week Range

$ 27.99 - $ 50.99

Volume

320,772

Average Volume

Market Cap

2.71B

Beta (5Y Monthly)

$ 0.90

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	02-29-2024	12-31-2023	10-K
2	11-08-2023	09-30-2023	10-Q
3	08-09-2023	06-30-2023	10-Q
4	05-09-2023	03-31-2023	10-Q
5	03-01-2023	12-31-2022	10-K
6	11-08-2022	09-30-2022	10-Q
7	08-09-2022	06-30-2022	10-Q
8	05-10-2022	03-31-2022	10-Q
9	03-01-2022	12-31-2021	10-K
10	11-10-2021	09-30-2021	10-Q
11	08-11-2021	06-30-2021	10-Q
12	05-11-2021	03-31-2021	10-Q
13	03-01-2021	12-31-2020	10-K
14	11-05-2020	09-30-2020	10-Q
15	08-06-2020	06-30-2020	10-Q
16	05-21-2020	03-31-2020	10-Q
17	03-09-2020	12-31-2019	10-K
18	11-05-2019	09-30-2019	10-Q
19	08-06-2019	06-30-2019	10-Q
20	05-07-2019	03-31-2019	10-Q
21	03-06-2019	12-31-2018	10-K
22	11-06-2018	09-30-2018	10-Q
23	08-07-2018	06-30-2018	10-Q
24	05-08-2018	03-31-2018	10-Q
25	03-07-2018	12-31-2017	10-K
26	11-07-2017	09-30-2017	10-Q
27	08-03-2017	06-30-2017	10-Q
28	05-09-2017	03-31-2017	10-Q
29	03-08-2017	12-31-2016	10-K
30	11-03-2016	09-30-2016	10-Q
31	08-03-2016	06-30-2016	10-Q
32	05-10-2016	03-31-2016	10-Q
33	03-08-2016	12-31-2015	10-K
34	11-10-2015	09-30-2015	10-Q
35	08-13-2015	06-30-2015	10-Q
36	05-12-2015	03-31-2015	10-Q
37	03-12-2015	12-31-2014	10-K
38	12-15-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Xenon Pharmaceuticals Announced Two Oral P...
04/16/2024 12:41:40

Xenon's Oral Presentations at AANOral Presentation #005 (French et al.) "Interim, Long-term, Safety and Efficacy of XEN...

Needham Reiterates Buy on Xenon Pharmaceut...
04/12/2024 11:03:09

Needham analyst Serge Belanger reiterates Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and maintains $62 price target.

Cantor Fitzgerald Reiterates Overweight on...
04/10/2024 13:47:31

Cantor Fitzgerald analyst Josh Schimmer reiterates Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and maintains $65 p...

RBC Capital Maintains Outperform on Xenon ...
03/01/2024 15:46:12

RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and lowers the price targ...

Wedbush Maintains Outperform on Xenon Phar...
03/01/2024 13:41:57

Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and raises the price target from...

Needham Maintains Buy on Xenon Pharmaceuti...
03/01/2024 13:11:50

Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and raises the price target from $50...

Xenon Pharmaceuticals Anticipates Having S...
02/29/2024 21:03:59

Xenon Pharmaceuticals Q4 EPS $(0.64) Beats...
02/29/2024 21:03:08

Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of...

Earnings Scheduled For February 29, 2024
02/29/2024 10:15:24

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...

Earnings Outlook For Xenon Pharmaceuticals
02/28/2024 15:01:40

this-analyst-is-bullish-on-biohavens-approach-in-neuro-psych-space

This Analyst Is Bullish On Biohaven's Appr...
02/16/2024 18:58:46

Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion acro...

Xenon Pharmaceuticals Outlines Key Milesto...
01/08/2024 13:15:24

Completion of Patient Enrollment in XEN1101 Phase 3 X-TOLE2 Clinical Trial in Focal Onset Seizures Anticipated in Second Half o...

Citigroup Initiates Coverage On Xenon Phar...
01/04/2024 09:47:37

Citigroup analyst David Hoang initiates coverage on Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy rating and announces Pric...

B of A Securities Maintains Buy on Xenon P...
01/02/2024 15:48:41

B of A Securities analyst Jason Gerberry maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and raises the price targe...

Stifel Maintains Buy on Xenon Pharmaceutic...
12/18/2023 15:57:45

Stifel analyst Stephen Willey maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and raises the price target from $53 ...

4 Analysts Have This to Say About Xenon Ph...
12/08/2023 16:00:32

Baird Initiates Coverage On Xenon Pharmace...
12/08/2023 10:29:07

Baird analyst Brian Skorney initiates coverage on Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform rating and announces...

why-xenon-pharmaceuticals-stock-xene-is-seeing-blue-skies-today

Why Xenon Pharmaceuticals Stock (XENE) Is ...
11/30/2023 19:51:15

Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares are trading higher by 7.8% to $36.38 Thursday afternoon. The company announced ...

Xenon Pharmaceuticals Prices Its Upsized $...
11/30/2023 08:25:59

Xenon Pharmaceuticals announced the pricing of its upsized underwritten public offering of 8,461,542 common shares and, in lieu...

Xenon Pharmaceuticals Commences Underwritt...
11/29/2023 21:15:53

In addition, Xenon intends to grant the underwriters an option for a period of 30 days to purchase up to an additional $33.75 m...